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Abstract
Background: Prostate cancer is the most-diagnosed non-skin cancer among males in the US, and the second
leading cause of cancer-related death. Current methods of treatment and diagnosis are not specific for the disease.
This work identified an antibody fragment that binds selectively to a molecule on the surface of androgen-dependent
prostate cancer cells but not benign prostatic cells.
Results: Antibody fragment identification was achieved using a library screening and enrichment strategy. A library of
109 yeast-displayed human non-immune antibody fragments was enriched for those that bind to androgen-dependent
prostate cancer cells, but not to benign prostatic cells or purified prostate-specific membrane antigen (PSMA). Seven
rounds of panning and fluorescence-activated cell sorting (FACS) screening yielded one antibody fragment identified
from the enriched library. This molecule, termed HiR7.8, has a low-nanomolar equilibrium dissociation constant (Kd) and
high specificity for androgen-dependent prostate cancer cells.
Conclusions: Antibody fragment screening from a yeast-displayed library has yielded one molecule with high affinity
and specificity. With further pre-clinical development, it is hoped that the antibody fragment identified using this
screening strategy will be useful in the specific detection of prostate cancer and in targeted delivery of therapeutic
agents for increased efficacy and reduced side effects.
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Background
The overall breadth of prostate cancer and problems associated with it render it necessary to develop novel therapeutics and diagnostics for the disease. Prostate cancer is the
most-diagnosed non-skin cancer in the United States, with
an estimated 233,000 new diagnoses in 2014 alone [1]. It is
the second leading cause of cancer-related deaths among
males in the U.S., with an estimated 29,480 mortalities in
2014 [1]. The scope of this disease portends the necessity
in developing improved clinical tools for its treatment.
It is necessary to develop specifically targeted therapeutics and diagnostics to further aid in treatment of prostate
cancer. Current practices for prostate cancer are partially
effective; however they are not specific for the disease, causing many unwanted side effects and over-diagnoses. Therapeutic side effects can be serious and leave the possibility
for recurrence in a more aggressive, androgen-independent
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form [2-4]. For many non-localized cancers, chemotherapies are used which can be effective, however specific delivery would be more effective and cause fewer side effects
[5-8]. In addition to non-specific therapeutics, prostate cancer diagnosis using prostate specific antigen (PSA) blood
levels is no longer recommended for use by the United
States Preventive Services Task Force (USPSTF) [9-13].
This is because serum PSA levels are raised not only due to
cancerous prostates, but due to benign prostatic conditions
such as prostatic intraepithelial neoplasia (PIN), benign
prostate hyperplasia (BPH), and prostatitis [14]. Studies
have shown the specificity of the PSA test in prostate cancer diagnosis to be just 24%, meaning there is a 76% overdiagnosis rate, and that it will prevent just one prostate
cancer-related death in greater than 1000 men [11,15].
Many other biomarkers identified that may have some
diagnostic potential, however are not specific for prostate
cancer [16-18]. Therefore, it is necessary to develop molecular targeting mechanisms for clinical use against prostate cancer.

© 2014 Williams et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.

Williams et al. BMC Biotechnology 2014, 14:81
http://www.biomedcentral.com/1472-6750/14/81

An increasingly popular method to develop diseasespecific targeting molecules is through antibody fragment
library screening. Previous library screening methodologies
have been adapted for use in identifying molecules that
bind to whole-cell targets [19,20]. Additionally, screening
methods exist for utilizing antibody fragment libraries displayed on bacteriophage, bacteria, and yeast [21-23]. Antibody fragments that bind to cell surfaces have largely been
selected from phage-displayed libraries, with examples
including those that bind to ovarian, breast, and hepatocellular carcinoma cells [24-26]. It is therefore possible to
identify antibody fragments which bind to the surface of
prostate cancer cells.
The work described here enriches an antibody fragment
library for molecules which bind to androgen-dependent
prostate cancer cells. Additionally, multiple stringent negative enrichments using targets to which the antibody fragment should not bind were selected against. This work has
identified an antibody fragment which binds to androgendependent prostate cancer cells, and not to various benign
prostate cells. It utilized a human non-immune singlechain Fragment variable (scFv) library displayed on the
surface of Sacchoromyces cerevisiae. It is hoped that the
obtained scFv will be useful for both specific treatment
and diagnosis of prostate cancer and serves as proof-ofprinciple for future screening of disease-specific antibody
fragments.

Results
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in any library or between the libraries. This suggests that
no particular sequence was selected for in these rounds.
After three rounds, FACS-based screening was performed. In Round 4 (+), there were two separate populations of yeast binding to target cells which were kept
separate through the remaining rounds of screening and
termed ‘Hi’ and ‘Lo’ (Additional file 1: Figure S1). After
Round 4, the Lo population was comprised of 29%
HiR7.8 (Figure 2). Interestingly, HiR7.6 and HiR6.8 were
not identified in the Lo population. HiR7.8 comprised
100% of the population in Rounds 6 and 7. This suggests
that HiR7.8 out-competed all other molecules in the Lo
population. It should be noted that HiR7.6 and HiR7.8
are both truncated sequences containing only the heavy
chain, while HiR6.8 is a full-length scFv (Table 2).
In the Round 4 Hi population, however, HiR7.6 comprised 52% of the population, while HiR6.8 was 26%.
Interestingly, HiR7.8 did not appear in the Round 4 Hi
population. In the Round 6 population, 77% of the library was HiR7.6 while 3% was HiR6.8. HiR7.8 now
comprised 20% of the library. In Round 7, HiR6.8 was
no longer detected, while HiR7.6 was now just 16% of
the library. HiR7.8 comprised 84% of the library, suggesting it strongly outcompeted HiR7.6. It is also of note
that HiR7.6 and HiR7.8 did not appear in any previous
library sequencing, however HiR6.8 did appear once in
the Round 3 library. This enrichment and convergence
upon HiR7.8 validates the sequence enrichment capabilities of this dual-method screening strategy.

Antibody fragment screening

In order to obtain androgen-dependent prostate cancer cell-specific antibody fragments, seven rounds of
screening and enrichment were completed with a yeastdisplayed scFv library [23] (Figure 1, Table 1). Sequencing
of a random, representative sample of the scFv-encoding
plasmid in the initial naïve library, as well as after Round 2
and Round 3 of panning, was performed. Out of the 30–
35 sequences identified, there were no duplicate sequences

Affinity binding assays of scFvs

Once HiR7.8 and HiR6.8 was identified for further
characterization, each was cloned into a secretion vector,
expressed, purified, and verified by polyacrylamide gel
electrophoresis (PAGE). These were used in fluorescent
saturation binding assays with LNCaP cells as described
in the Methods, plotted, and fit with nonlinear regression analysis (Figure 3). HiR6.8 exhibited an equilibrium

Figure 1 Library screening and enrichment strategy utilized to identify a prostate cancer cell-specific antibody fragment.
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Table 1 In vitro selection scheme for selecting an androgen-dependent prostate cancer cell-specific scFv
Selection round

Target

Yeast number

Human cell number

Incubation time (hours)

Incubation volume (mL)

Separation method

1 (+)

LNCaP

1 × 1010

~8 × 106

3

15

Panning

1 (−)

HGPIN

1 × 1010

~7 × 106

0.5

15

Panning

~9 × 106

0.5

~7.5 × 106

0.5

~9 × 106

BPH-1
BHPrE1
2 (+)
2 (−)

LNCaP
HGPIN

10

1 × 10

10

1 × 10

BPH-1

3 (−)

LNCaP
HGPIN

~8.5 × 10

1

15

Panning

~9.5 × 106

1
1

~9 × 106

1

15

Panning

10

6

~7 × 10

2

15

Panning

~9 × 106

2

FACS

1 × 10

1 × 10

~8 × 106

2

7

1 × 106

0.5

2.5

7

6

BHPrE1
LNCaP

Panning

~8 × 106

BPH-1

4 (+)

15

10

BHPrE1
3 (+)

2
6

1 × 10

4 (−) a

HGPIN

1 × 10

1 × 10

0.5

1.5

FACS

4 (−) b

BPH-1

1 × 107

1 × 106

0.5

2

FACS

4 (−) c

BHPrE1

1 × 107

1 × 106

0.5

1.5

FACS

4 (−) d

PSMA

1 × 10

1 nmol protein

0.5

1

FACS

5 (+)

LNCaP

1 × 107

1 × 106

0.5

5

FACS

LNCaP

7

1 × 105

0.5

2.75

FACS

7

6

6 (+)

7

1 × 10

6 (−) a

HGPIN

1 × 10

1 × 10

0.5

2.5

FACS

6 (−) b

BPH-1

1 × 107

1 × 106

0.5

2.5

FACS

7

6

6 (−) c

BHPrE1

1 × 10

1 × 10

0.5

2.5

FACS

6 (−) d

PSMA

1 × 107

1 nmol protein

0.5

2

FACS

7 (+)

LNCaP

1 × 107

1 × 103

0.5

2.5

FACS

dissociation constant (Kd) of 33.2 +/− 22.2 nM. A Kd of
27.3 +/− 15.9 nM was obtained for HiR7.8.
Binding of each scFv for androgen-dependent prostate
cancer cells is further evidenced by fluorescent micrographic analysis. Binding of each scFv is clear when preincubated with a secondary fluorescent antibody and
then with target cells and imaged for fluorescent staining
(Figure 4C and D). Fluorescence is much brighter than
target cells incubated with fluorescent secondary-only

control (Figure 4B) and comparable to the positive control (Figure 4A). Interestingly, both antibodies have a
horseshoe-like staining pattern for each cell. Therefore,
fluorescence may be visualized in the cytosol surrounding the nucleus.
Specificity binding assays of scFvs

Purified scFvs were each assayed for their ability to bind
to cell lines other than LNCaP. These included the

Figure 2 Sequence enrichment in the enriched scFv library in both the Lo and Hi populations beginning in Round 4.
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Table 2 Amino acid sequences of HiR6.8, HiR7.6, and HiR7.8
Sequence
name

Sequence

Predicted molecular
weight

HiR6.8

DVPDYALQASGGGGSGGGGSGGGGSASQVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGWINPNSG
GTNYAQKFQGRVTMTRDTSISTAYMELSSLRSDDTAIYYCARDADSGSMSAIYWYFNLWGRGTLVTVSSGILGSGGGGSGGGGSGGGGS
DIQLTQSPSSLSASVGDRVTITCRASQSISRFLNWYQQKPGKAPKLLIYGGSSLQSGVPSRFSGGGSGTDFTLTISSLQPE
DFATYYCQQSYSKFWTFGQGTKVEIKSGILEQKLISEEDL

30.6 kDa

HiR7.6

DVPDYALQASGGGGSGGGGSGGGGSASQVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKELEWIGEIHHSGS 15.6 kDa
TNYNPSLKSRVTISVDKSKNQFSLKMRSVTAADTAVYYCARVEEWPYDALDMWGQGTMVTVSSEF

HiR7.8

DVPDYALQASGGGGSGGGGSGGGGSASQVQLQESGPGLVKPSQTLSLTCTVSGDSIYSSGHYWSWVRQHPGKGLEWIGYIYAS
GRTYYNPSLESRVTMSVDTSKNQSSLKLTSVTAADTAVYYCARDDSRTWYKAFDTWGQGTMVTVSSEF

16.0 kDa

Italicized amino acids represent the heavy chain. Bold amino acids represent the light chain. HiR7.6 and HiR7.8 do not contain a light chain. Non-italicized or
bolded amino acids represent scFv structural elements.

negative targets in the screening strategy, HGPIN, BPH1, and BHPrE1 (Figure 5A & B). They also included
androgen-independent prostate cancer cell lines DU-145
and PC-3 as well as normal prostate epithelium cell lines
RWPE-1 and NHPrE1 (Figure 5C & D).
From these experiments, it is clear that HiR6.8 binds to
all three negative cell lines as well as the other four lines
assayed (Figure 5A & B). Binding to many of these lines
was as good or better than binding to LNCaP cells. This is
a likely explanation as to why HiR6.8 was eliminated from
both populations, in spite of its low dissociation constant.
HiR7.8, however, showed excellent selectivity for LNCaP
cells (Figure 5C & D). Binding to HGPIN, BPH-1, and
BHPrE1 cells all were much less than to the target cancer
cells. Subtraction of background secondary antibody MFI
from scFv binding resulted in negative numbers due to
binding of the secondary antibody to the scFv and not the
cell lines. Additionally, binding to the four cell lines not

used in screening and enrichment was significantly less
relative to binding to target cells. In sum, this suggests that
HiR7.8 is highly specific to androgen-dependent prostate
cancer cells and therefore will be useful in both the therapeutic targeting and disease detection of prostate cancer.

Discussion
The library screening and enrichment strategy used in this
work focused on multiple, stringent negative enrichment
targets to identify a scFv specific for androgen-dependent
prostate cancer cells. Three rounds of panning were performed to remove scFvs with very low target affinity or
that bound to molecules highly expressed on other cell
surfaces [27]. There was a large amount of diversity
present in the library however, so a more stringent separation method, FACS, was employed [28]. Initial use
of FACS would have been unsuccessful as prior work
has shown the efficiency of FACS is poor at low

Figure 3 Equilibrium dissociation constants for HiR7.8 and HiR6.8. The graph depicts a representative saturation binding curve for HiR7.8
fit with nonlinear regression analysis. The table reports the dissociation constant (Kd) of both scFvs in nM averaged from three assays with
standard errors.
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Figure 4 Representative fluorescent micrographs of LNCaP cells
bound by identified scFvs. Images are at 630X magnification.
(A) Image of cells tagged with fluorescent anti-PSMA antibody.
(B) Image of cells incubated with anti-HA secondary fluorescent
antibody. (C) Image of cells incubated with HiR6.8 and secondary
antibody. (D) Image of cells incubated with HiR7.8 and secondary
antibody.
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concentrations of the binding population [29,30]. Thus,
removal of non-binding molecules increased the concentration of binding scFv in the population, allowing
successful FACS isolation due to its single-cell and quantitative nature, as has previously been described [30,31].
Additionally, the initial library size was much too great to
efficiently analyze single cells in a reasonable time span.
Thus, panning followed by FACS was utilized, and the
strong enrichment of the identified random sample of the
library validates this strategy.
From the obvious enrichment through seven rounds of
screening (Figure 2), HiR7.8 was chosen as the most
likely prostate cancer cell-specific antibody fragment and
underwent further characterization. However, as a representative of scFvs present in earlier rounds of screening
and to determine why it was outcompeted, HiR6.8 was
also chosen for further characterization. It is also important to note that HiR6.8 is a full-length scFv, comprising both a heavy and light chain, with a predicted
molecular weight of approximately 30.6 kDa for the scFv
itself. HiR7.8 and HiR7.6, however, only contain a heavy
chain, as they are truncated just before the chain linker.
They have a predicted molecular weight of approximately 16.0 and 15.6 kDa, respectively, and have 81%

Figure 5 Cross-binding assays of HiR6.8 and HiR7.8. (A) HiR6.8 binding to negative target cell lines used throughout screening and (B) cell
lines not used as negative targets in screening. (C) HiR7.8 binding to negative target cell lines used throughout screening and (D) cell lines not
used as negative targets in screening. Average values are graphed and normalized to target cells with errors bars representing standard
deviations for three assays. * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
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sequence identity and 86% sequence similarity. This may
be relevant in vivo, as it has been shown that smaller
scFvs have greater tumor penetration ability than larger
antibodies [32]. It is possible that truncated scFvs will
suffer from decreased stability. Future work will assay
stability in envisioned applications and, if necessary, perform mutagenesis to select stable variants [33] or insert
it into the scaffold of a stable full antibody [34].
The dissociation constants for each of these scFvs are
in the low-nanomolar range, which is similar to previous
reports of scFvs isolated from similar screening strategies [35-37]. More importantly, it is in a similar range
to other antibody fragments that have strong pharmacokinetic properties [38,39]. It is possible that further mutagenesis and screening may select for scFvs with higher
affinity for the cell surface target [37,40].
It may be possible that fluorescent staining images represent cellular uptake of the scFv-secondary antibody complex due to the cytoplasmic pattern. This has previously
shown to be possible and even likely with scFvs alone or in
complex with other molecules [41-43]. If these scFvs are
taken up by androgen-dependent prostate cancer cells, this
may have an important role in the clinical application of
these scFvs. The potential ability to use these scFvs as
therapeutic targeting agents in the form of antibody-drug
conjugates (ADCs) is enhanced by scFv internalization [44].
Potential uptake of the scFv by androgen-dependent prostate cancer cells will be explored in future studies.
Biologically, the selectivity of HiR7.8 for androgendependent prostate cancer cells is important. HiR6.8
clearly binds to other cell lines tested, and this is likely the
cause of its depletion from the library as the stringency of
FACS enrichment increased. This depletion seems to validate the powerful selectivity of the FACS screening strategy. There is an absence of binding to all benign cell lines
studied, whether they represent normal prostatic cells,
BPH, or PIN. This suggests that the cell surface molecule
HiR7.8 is binding to is not displayed on the surface of benign prostatic cells. This is supported by previous studies
that have identified many genes differentially expressed
between the benign conditions represented here and prostate cancer cells [45-47]. Additionally, there is no binding
to the androgen-independent prostate cancer cell lines
DU-145 or PC-3. This suggests that the cell surface antigen is displayed in the earlier, androgen-dependent stage
of prostate cancer. This is possible considering previous
studies have found a wide array of genes that are differentially expressed from androgen dependent to independent
disease progression, many of which are downregulated
[48-50]. In fact, downregulation of expression levels from
LNCaP to both DU-145 and PC-3 cells has been found before [51-54] Future work will determine binding to other
androgen-dependent prostate cancer cells utilizing antigen
capture techniques coupled with mass spectrometry.
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Determining binding will be aided by identifying the exact
cell surface molecule to which HiR7.8 is binding, as has
been done before with similar cell surface antigen-binding
molecules [55,56]. This type of work has even identified
novel cell surface molecules previously unknown to be involved in disease progression [57]. It is therefore possible
that this work not only created a novel targeting agent,
but also identified a novel target.
The high affinity and specificity of HiR7.8 for androgendependent prostate cancer cells suggest it has potential in
future therapeutic and diagnostic applications in prostate
cancer. Though not determined here, future work will
determine its binding to tissue representing androgendependent prostate cancer and other prostatic diseases
which will determine the translational potential of the
molecule. It is likely, however, that HiR7.8 will bind to
androgen-dependent prostate cancer tissue from patients
based on binding specificity and affinity similar to
previously-identified molecules [58]. The selective scFv
will likely be useful for drug delivery as has been shown
before [59-62]. It has previously been noted that scFvs
have much less immunogenicity than full antibodies in
part due to their size and lack of an Fc component
[63-65]. Additionally, it will likely have use in specific diagnosis of prostate cancer whether in or ex vivo [66-69].
Finally, identification of the cell surface markers to which
these scFvs bind may possibly identify novel proteins, new
functions, or expression patterns that aid in treatment and
diagnosis of prostate cancer and will be done in future
work. This cell surface molecule and its expression pattern
in androgen-dependent prostate cancers will determine
the translation of the identified scFv beyond the cells used
here. While it is likely to be useful in a defined set of prostate cancers, the antibody fragment screening strategy
described here also serves as a proof-of-principle for selection of other disease-specific antibody fragments.

Conclusions
This work has selected a scFv antibody fragment, HiR7.8,
with high affinity for androgen-dependent prostate cancer
cells. Furthermore, the selected molecule has a high selectivity for the target cells and not for benign prostatic cells
or for androgen-independent prostate cancer cells. These
characteristics will allow the selected scFv to be useful for
both therapeutic and diagnostic applications in the clinical
treatment of prostate cancer with further pre-clinical development. With targeted therapeutics and more specific
diagnostics, it is possible that increased efficacy and reduced side effects of treatments as well as earlier disease
detection will be realized by the scFv obtained here.
Methods
A library screening and enrichment process was used in
order to obtain an androgen-dependent prostate cancer
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cell-specific antibody fragment (Figure 1). A library of
non-immune human single-chain Fragment variable
(scFv) antibody fragments, displayed on the surface of
Saccharomyces cerevisiae, was a generous gift from Dr.
Dane Wittrup (Massachusetts Institute of Technology;
Cambridge, MA) [23]. Seven rounds of screening were
completed, enriching for those scFvs which bound to
androgen-dependent prostate cancer cells and subtracting those that bound to benign prostate cell lines as well
as the protein PSMA.

Cell culture and materials

In order to obtain a prostate cancer cell-specific scFv,
prostatic cell lines were used. For general maintenance,
each line was passaged every 5–7 days in a T75 cell culture dish with media changed every 2–3 days. The cells
were grown in a 37°C incubator with 5% carbon dioxide
and humidity. The LNCaP cell line was used as a model
of androgen-dependent prostate cancer and was the target of positive enrichment. It was obtained from the
American Type Culture Collection (ATCC) (Manassas,
VA) and cultured in RPMI 1640 with L-Glutamine and
25 mM HEPES (Cellgro; Manassas, VA) and 10% Fetal
Bovine Serum (FBS) (Fisher Scientific; Pittsburgh, PA)
and 1X antibiotic/antimycotic mixture (ab/am) (Cellgro) [70]. The High Grade Prostatic Intraepithelial Neoplasia (HGPIN) cell line was a generous gift from Dr.
Mark Stearns (Drexel University; Philadelphia, PA) and
was cultured in Defined KSFM (Gibco; Grand Island,
NY) with 5% FBS and 1X ab/am [71]. The Benign Prostate Hyperplasia (BPH-1) cell line was a generous gift
from Dr. Simon Hayward (Vanderbilt University; Nashville, TN) and was cultured in RPMI-1640 with LGlutamine and 25 mM HEPES and 10% FBS and 1X ab/
am [72]. The intermediate prostate stem cell line
BHPrE1 was also a generous gift from Dr. Simon
Hayward and cultured in DMEM/F12 (Cellgro) supplemented with 5% FBS, 1X ab/am, 1% insulin/transferrin/
selenium (Gibco), 0.4% bovine pituitary extract (Sigma;
St. Louis, MO), 5 ng/mL epidermal growth factor
(Gemini Bio-Products; West Sacramento, CA), and 1X
ab/am [73]. The androgen-independent DU-145 prostate cancer cell line was obtained from ATCC and cultured in EMEM (Cellgro) with 10% FBS and 1X ab/am
[74]. The androgen-independent prostate cancer cell
line PC-3 was also obtained from ATCC and cultured in
F12K media (Cellgro) with 10% FBS and 1X ab/am [75].
The normal prostatic epithelium cell line RWPE-1 was
obtained from ATCC and cultured in Defined KSFM
(Gibco) plus 1X ab/am [76]. The early prostate stem cell
line NHPrE1 was a generous gift from Dr. Simon Hayward
(Vanderbilt University) and cultured in the same media as
BHPrE1 [73].
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scFv library and growth

A human non-immune scFv library with 109 diversity
displayed on the surface of Sacchoromyces cerevisiae was
utilized [23,28]. The yeast library was chosen due to its
amenability to FACS screening and the ability of yeast to
display post-translationally modified proteins due to
their eukaryotic nature. The library was amplified and
expression induced as previously described [23,28]. Before each screening incubation, expression was verified
by tagging with a monoclonal anti-HA tag antibody conjugated to either DyLight 488 (Columbia Biosciences;
Columbia, MD) or AlexaFluor 488 (Invitrogen; Grand
Island, NY). The samples were run on either a Cell Lab
Quanta SC (Beckman Coulter; Brea, CA) or a FACSCalibur
(BD Biosciences; San Jose, CA) flow cytometer equipped
with a 488 nm argon laser and 525 nm emission filter.

Library screening

Seven rounds of screening were performed in order to
obtain a scFv specific for androgen-dependent prostate
cancer cells (Table 1). The first three rounds of screening were performed by panning and the last four by
fluorescence-activated cell sorting (FACS).
For Round 1(+) screening, androgen-dependent LNCaP
prostate cancer cells were grown to 80-90% confluency
and the media was removed. The cells were gently washed
with calcium- and magnesium-free phosphate-buffered saline (PBS). The cells were then incubated with 1010 yeast
from the naïve library in 15 mL yeast screening buffer
(YSB) containing PBS, 0.5% bovine serum albumin (BSA)
and 1% FBS. The library was placed into the flask containing prostate cells and placed on a 37°C shaker at 25 RPM
for three hours. After incubation, yeast not bound to the
cells were removed, and the LNCaP cells were gently
washed three times with 15 mL YSB and confluence of
remaining attached cells was visually confirmed. 100 mL
yeast amplification media was added to the flask to allow
for amplification of yeast bound to the prostatic cells. This
was grown overnight, and this enriched library was prepared for a round of negative enrichment. For Round 1(−)
screening, scFv-expressing yeast were suspended in YSB
and incubated with rinsed HGPIN cells at 80-90% confluency for 30 minutes at 37°C with shaking at 25 RPM.
The supernatant containing yeast-displayed scFvs not
bound to HGPIN cells was removed and added to rinsed
BPH cells under the same conditions, removed again and
added to rinsed normal prostatic epithelium BHPrE1 cells
under the same conditions. The serially-incubated supernatant was centrifuged to obtain yeast, which were amplified. Two more rounds of panning were performed in
this manner, with decreasing incubation times for positive rounds and increasing incubation times for negative
rounds.
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The ensuing four rounds of screening were performed
using FACS-based separation (Additional file 1: Figure S1).
For Round 4(+), LNCaP cells grown to 80-90% confluency
were fluorescently dyed with CFSE (Invitrogen) according
to manufacturer’s instructions. They were then dissociated
from the flask with Cellstripper reagent (Cellgro) to prevent cell surface protein digestion associated with trypsinization. Cells were then suspended in YSB and counted
with a Scepter equipped with 60 μm sensors (Millipore;
Billerica, MA). In Round 4, all yeast were fluorescently
dyed with Syto61 (Invitrogen) according to manufacturer’s
instructions. A total of 107 yeast were suspended in YSB
and mixed with 106 LNCaP in 2.5 mL. They were mixed
by inversion for 30 minutes at 37°C and placed on ice before FACS sorting. The sample was then sorted with a
FACSAria (BD Biosciences), with excitation at 488 nm
from a sapphire solid state laser and 633 nm from a HeNe
laser and 525 nm and 650 nm emission filters. Events
identified as bound yeast and prostate cells were collected.
In Round 4(+), there were two separate populations of
bound cells which were collected and amplified separately.
These were named the ‘Hi’ and ‘Lo’ populations and kept
separate through the following rounds of screening and
subjected to the identical conditions.
In Round 4(−)a, for each of the Hi and Lo populations,
yeast were prepared for screening in the same manner
and incubated with 106 HGPIN cells dyed the same with
inversion for 30 minutes at 37°C in YSB. The sample
was subjected to FACS and events that indicated yeast
that were not bound to HGPIN cells were collected and
amplified. Those were then incubated with 106 dyed
BPH cells for Round 4(−)b and subjected to FACS with
unbound yeast collected and amplified. The enriched library was then prepared for Round 4(−)c and subjected
to FACS after incubation with 106 dyed BHPrE1 cells.
Unbound yeast were collected and amplified, then prepared for screening and incubated with 1 nmol recombinant full-length PSMA protein, which is expressed in
non-prostatic normal and tumor tissue, as well as normal prostate cells [77] (Abnova #H00002346-P01; Walnut,
CA). This protein is 107 kDa and 719 amino acids with a
GST tag and was pre-incubated with AlexaFluor 488conjugated anti-GST tag antibody (Invitrogen). The yeast
which showed single fluorescence signals corresponding
to Syto61 were kept and amplified. Positive enrichment
rounds continued through Round 7, with yeast fluorescent
tagging being done with anti-HA tag antibody conjugated
to AlexaFluor 647 (Invitrogen) with decreasing target cell
concentrations. This tagging method was used for a negative enrichment performed in Round 6.
Sequencing of scFv library

A representative sample of scFv genes from the naïve library (Round 0) was sequenced to determine diversity of
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the library. Additionally, this was completed for the
enriched post-Round 2(−) and post-Round 3(−) libraries.
It was also performed for each of the Hi and Lo populations following Round 4(−), Round 6(−) and Round 7(+).
To do this, yeast were plated onto amplification media
agar, and individual colonies were chosen for polymerase
chain reaction (PCR) amplification.
Yeast colonies were picked and placed into double distilled water and boiled, which served as template for the
PCR reaction. The reaction ingredients were as follows:
400 nM forward (5′-GTACGAGCTAAAAGTACAGTG3′) and reverse (5′-TAGATACCCATACGACGTTC-3′)
pPNL6 primers (Eurofins MWG Operon), 250 μM
deoxynucleotide triphosphates, 5% dimethyl sulfoxide,
1X Phusion Reaction Buffer (New England Biolabs, Ipswich,
MA), 2 units Phusion High-Fidelity DNA polymerase
(New England Biolabs), and double distilled water to
100 μL. Reactions conditions were: initial denaturation at
98°C for 30 seconds; 35 cycles of 98°C for 10 seconds,
50°C for 30 seconds, and 72°C for 30 seconds; and final
extension at 72°C for 10 minutes. Results were analyzed
using agarose gel electrophoresis and those PCRs that
contained bands corresponding to the scFv gene were
purified using a PCR purification kit (IBI Scientific; Peosta,
IA) and sent for DNA sequencing (Eurofins MWG Operon; Huntsville, AL) using both the forward and reverse
pPNL6 primers. In total, 30–35 sequences were obtained
for each enriched library noted above, including for individual Hi and Lo populations separately. Analysis was then
performed by translating the DNA sequence to protein
using the ExPASy translate tool (Swiss Institute of Bioinformatics; http://web.expasy.org/translate/). Hemagluttanin, c-Myc, and linker protein tag sequences, landmarks
of the scFv expression scaffold, were identified to ensure
sequence quality [23]. Sequences were compared for similarities and duplicates within an enriched library were
identified to determine diversity of a random sample of
the library.
Secretion and purification of selected scFvs

From the Rounds 6(−) and 7(+) sequences, one scFv,
HiR7.8, was chosen for further study due to its abundance
in the enriched libraries. HiR6.8 was also chosen to be representative of scFvs present earlier in the screening
process and to determine why it was outcompeted from
the population by HiR7.8. These sequences were subcloned into the pPNL9 secretion vector in YVH10 yeast
using gap repair essentially as previously described [28].
For truncated scFv sequences, a modified reverse PCR
primer (5′- GGGTTAGGGATAGGCTTACCGAACTCT
GAAGAGACGGTGACC-3′) was used. After growth of
the yeast containing the scFv sequence within the secretion vector, the supernatant was recovered and scFv purified with Ni-NTA resin following the manufacturer’s
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protocol (Thermo Scientific; West Palm Beach, FL). Purified scFv was analyzed by polyacrylamide gel electrophoresis as previously reported, and the concentration of the
scFv was determined using spectroscopy with a NanoDrop
(Thermo Scientific). The scFv was then diluted to a working concentration of 10 μM in PBS.
Affinity binding assays with scFvs

In order to determine the binding affinity of the secreted
scFvs with the target androgen-independent prostate
cancer cells, saturation binding assays were performed
essentially as previously described [36,40]. LNCaP cells
were grown to 80-90% confluency and removed from
the flask with CellStripper reagent. They were counted
and 2 × 105 cells were placed into a 500 μL total volume
of YSB. For saturation binding assays, the appropriate
amount of scFv was incubated on ice for 30 minutes
with 2 μL of the monoclonal anti-HA antibody conjugated to DyLight 488 (Columbia Biosciences). Concentrations of 0, 1, 10, 100, 1000, 10000, 50000, 100000,
150000, 200000 pM of the scFv were used. The preincubated scFv and secondary antibody were mixed with
LNCaP cells and placed on a rotisserie at 37°C for 30 minutes. After this period, the cells were washed and run
on a FACSCalibur (BD Biosciences) as previously described. The mean fluorescence intensity (MFI) for each
sample was recorded. The MFI for the 0 pM incubation,
which had only the secondary fluorescent antibody, was
subtracted from the MFI of each incubation. These data
were graphed using Origin 8 software (OriginLab Corporation; Northampton, MA). The data were fit with a
nonlinear regression model of single-event binding given
by the equation, Y = ((Bmax*X)/(Kd + X)) + NS*X, where
Bmax is maximum binding, Kd is the dissociation constant, and NS is nonspecific binding [78]. Each assay was
performed in triplicate, with the Kd values averaged and
the standard errors of the Origin-obtained Kd values
were combined.
Fluorescent imaging of scFv binding

In order to visualize binding of each scFv, fluorescent
images were taken. Target androgen-independent prostate cancer cells were grown in a 6-well culture dish on
number 1.5 microscopic cover glasses to ~90% confluency. For each secreted scFv, a 100 nM concentration
was pre-incubated with anti-HA antibody conjugated to
DyLight 488 as described for binding assays. Cells incubated with anti-PSMA AlexaFluor488 antibody served as
a positive control (BioLegend; San Diego, CA) and cells
incubated with only anti-HA DyLight 488 antibody
served as negative control. Cells were incubated at 37°C
for 30 minutes with shaking at 25 RPM. The supernatant
was removed and the cells were washed, formalin-fixed,
and mounted onto microscope slides. Cells were imaged
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on a Zeiss AxioImager Z2 Fluorescent Microscope (Zeiss;
Thornwood, NY) using an Argon laser at 488 nm for excitation with a band pass emission filter at 505–530 nm.
Specificity binding assays of scFvs

In order to determine the specificity of scFv binding,
cross-binding assays were performed with the cells used
as negative targets. LNCaP, HGPIN, BPH-1, and BHPrE1
cells were counted and 2 × 105 cells were placed into
500 μL YSB. Concentrations of 0 or 100 nM scFv were
incubated with the secondary anti-HA AlexaFluor 488
antibody for 30 minutes on ice. Cell were prepared as
described above and then run on a FACSCalibur and the
MFI recorded. The MFI of the 0 pM incubation, which
had only the secondary fluorescent antibody, served as
background fluorescent labeling and was subtracted
from the 100 nM incubation. Data were normalized to
target cell binding, which was set to 100%, and graphed
to show comparative binding between the cell lines.
In order to determine binding to other prostatic cell
lines not used throughout screening, cross-binding assays
were performed. The target androngen-dependent prostate cancer cells, the androgen-independent prostate cancer cell lines DU-145 and PC-3, and the normal prostatic
cell lines RWPE-1 and NHPrE1 were used for this experiment. The cells were prepared as noted above and run on
a FACSCalibur. Each set of cross-binding assays were performed in triplicate and significance in the differences of
means were obtained using a student’s T-test.

Additional file
Additional file 1: Figure S1. Representative FACS plots from the
selection. For all, the X-axis is CFSE fluorescence, which was used to stain
the target cell line and the Y-axis is Syto 61 or Alexa647 (anti-HA
antibody) which was used to stain yeast expressing the library. Q1 shows
stained yeast alone, Q2 shows events representing yeast bound to the
target cell line, Q3 shows stained cells alone, and Q4 shows unstained
cells and debris. A) FACS plot from Round 4(+) selection with the target
LNCaP cell line. The origination of the “Hi” and “Lo” populations are
shown and so named due to amount of yeast staining present in the
events. B) FACS plots from Round 5(+) selection with the target LNCaP
cell line. Left shows sorting of the yeast binding to the LNCaP cell line
in the Lo population and right shows sorting of the yeast binding to the
LNCaP cell line in the Hi population. C) FACS plots from Round 6(-)c
selection with the non-target BHPrE1 cell line. Left shows sorting of yeast
that did not bind to BHPrE1 cells in the Lo population and right shows
sorting of yeast that did not bind to the BHPrE1 cells in the Hi
population.
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